Coblopasvir

Coblopasvir (KW-136) is a pangenotypic non-structural protein 5A (NS5A) inhibitor. Coblopasvir can be used for research of chronic hepatitis C virus infection[1].

Product Specifications

CAS Number

[1312608-46-0]

Product Name Alternative

KW-136

UNSPSC

12352005

Target

HCV; HCV Protease

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/coblopasvir.html

Solubility

10 mM in DMSO

Smiles

O=C(N[C@H](C(N1[C@@H](CCC1)C2=NC(C3=CC=C(C=C3)C4=C5OCOC5=C(C=C4)C6=CNC([C@H]7N(CCC7)C([C@H](C(C)C)NC(OC)=O)=O)=N6)=CN2)=O)C(C)C)OC

Molecular Formula

C41H50N8O8

Molecular Weight

782.88

References & Citations

[1]Gao Y, et al. Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial. Liver Int. 2020;40 (11) :2685-2693.